The short answer
Chromium may add to insulin’s glucose-lowering effect, so supplement use warrants an individual monitoring plan. A regular-human-insulin-specific risk or chromium requirement has not been established.
What this answer covers
Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
- Supplement or preparation
- Chromium
- Medication ingredient
- insulin, regular, human
Why monitoring is reasonable
NIH guidance cautions that chromium may increase glucose-lowering effects when combined with insulin. The regular-insulin labels call for review when glucose-active treatments change. This is a conditional precaution, not a measured interaction rate.
The direct drug trial used glipizide
A chromium-picolinate study improved insulin sensitivity and glucose control in people taking glipizide GITS. Glipizide stimulates insulin secretion and is not injected regular human insulin. That study cannot quantify the risk for this pair.
No extra chromium need follows
The trial does not show that regular human insulin depletes chromium or that every insulin user should supplement. Chromium form, elemental dose and overlapping products need review, particularly with high-dose preparations.
Monitoring is more useful than assumed spacing
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. No hour-based gap has been shown to remove chromium’s possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
Federal chromium-insulin precaution supports monitoring, with no regular-insulin-specific incidence.
- Exact scope
- Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium. with Regular human insulin RxCUI253182 IN; U100/U500 and routes distinct.
- Medication form and route
- injected regular human insulin; oral supplement
What remains uncertain
- No exact herb-event rate or arbitrary insulin change.
Factors that may matter: Concentration; Route; Meals; Product; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed regular human insulin
Hypoglycemia can be severe. Niacin may decrease glucose lowering. Treatment changes can require increased monitoring and clinician review. Subcutaneous dose given30minutes before meals.
How this applies: Exact RxCUI253182 IN regular human insulin; U100/U500 distinguished from NPH and rapid analogs.
Product concentration, devices, route and action profile matter. No supplement-specific adverse-event incidence.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed regular human insulin
Hypoglycemia can be severe. Niacin may decrease glucose lowering. Treatment changes can require increased monitoring and clinician review. Subcutaneous dose given30minutes before meals. Concentration gives a different time course with both prandial and basal activity.
How this applies: Exact RxCUI253182 IN regular human insulin; U100/U500 distinguished from NPH and rapid analogs.
Product concentration, devices, route and action profile matter. No supplement-specific adverse-event incidence.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact regular human insulin; source drug, preparation and endpoint retained.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement. This does not establish an exact regular-human-insulin interaction.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Indirect for exact regular human insulin; source drug, preparation and endpoint retained.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial. This does not establish an exact regular-human-insulin interaction.
Research assessment: · Open full citations ↗
Timing & monitoring
No established supplement requirement or protective spacing interval with regular human insulin; glucose monitoring does not demonstrate a nutrient need.
- Exact scope
- Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium. with Regular human insulin RxCUI253182 IN; U100/U500 and routes distinct.
- Medication form and route
- injected regular human insulin; oral supplement
What remains uncertain
- No exact herb-event rate or arbitrary insulin change.
Factors that may matter: Concentration; Route; Meals; Product; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed regular human insulin
Hypoglycemia can be severe. Niacin may decrease glucose lowering. Treatment changes can require increased monitoring and clinician review. Subcutaneous dose given30minutes before meals.
How this applies: Exact RxCUI253182 IN regular human insulin; U100/U500 distinguished from NPH and rapid analogs.
Product concentration, devices, route and action profile matter. No supplement-specific adverse-event incidence.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed regular human insulin
Hypoglycemia can be severe. Niacin may decrease glucose lowering. Treatment changes can require increased monitoring and clinician review. Subcutaneous dose given30minutes before meals. Concentration gives a different time course with both prandial and basal activity.
How this applies: Exact RxCUI253182 IN regular human insulin; U100/U500 distinguished from NPH and rapid analogs.
Product concentration, devices, route and action profile matter. No supplement-specific adverse-event incidence.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact regular human insulin; source drug, preparation and endpoint retained.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement. This does not establish an exact regular-human-insulin interaction.
Source 4: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Indirect for exact regular human insulin; source drug, preparation and endpoint retained.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial. This does not establish an exact regular-human-insulin interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact regular-insulin article with route, concentration and clinical endpoint boundaries. | |
| Research summary published |
Article revision: f132da21445f37f0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.